Published • loading... • Updated
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China
The approval gives Lilly a lead over Novo Nordisk as China’s obesity rate could top 65% by 2030, regulators said.
- On Nov 12, 2026, Eli Lilly received regulatory approval in China for a GLP-1 weight-loss pill, becoming the first company to gain this approval in the world's second-largest pharmaceutical market.
- Rising obesity rates in China prompted regulatory interest; the National Health Commission projects overweight or obese populations could reach more than 65% by 2030, up from roughly 50% in 2020.
- Lilly will compete against once-weekly GLP-1 injections from Novo Nordisk, Pfizer, and Innovent Biologics, though oral therapies may attract patients reluctant to use needles.
- Novo has also submitted an application to sell its oral Wegovy pill in China, though approval remains pending while the company trails Lilly in securing market entry.
- Yang Huang, head of China healthcare research at Morgan, forecasts annual GLP-1 sales could reach 30 billion yuan within the next five to seven years, up from 3 billion to 4 billion yuan currently.
Insights by Ground AI
8 Articles
8 Articles
Pharmaceutical giant Eli Lilly has just had its obesity pill approved in China, and there is great potential in the Chinese market.
·Copenhagen, Denmark
Read Full Article
Eli Lilly became the first company to obtain approval in China for the GLP-1-class slimming drugs, obtaining an advantage in front of the Danish rival Novo Nordisk on the second largest market in the world...
As an alternative to the weight loss syringe, Eli Lilly is launching a pill on the market. In China, it is the first approved weight loss pill. Thus, the US company is ahead of its competitors.
·Düsseldorf, Germany
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left1Leaning Right2Center5Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
13%
C 62%
R 25%
Factuality
To view factuality data please Upgrade to Premium
